CREB-binding protein sequestration by expanded polyglutamine
- PMID: 10958659
- DOI: 10.1093/hmg/9.14.2197
CREB-binding protein sequestration by expanded polyglutamine
Abstract
Spinal and bulbar muscular atrophy (SBMA) is one of eight inherited neurodegenerative diseases known to be caused by CAG repeat expansion. The expansion results in an expanded polyglutamine tract, which likely confers a novel, toxic function to the affected protein. Cell culture and transgenic mouse studies have implicated the nucleus as a site for pathogenesis, suggesting that a critical nuclear factor or process is disrupted by the polyglutamine expansion. In this report we present evidence that CREB-binding protein (CBP), a transcriptional co-activator that orchestrates nuclear response to a variety of cell signaling cascades, is incorporated into nuclear inclusions formed by polyglutamine-containing proteins in cultured cells, transgenic mice and tissue from patients with SBMA. We also show CBP incorporation into nuclear inclusions formed in a cell culture model of another polyglutamine disease, spinocerebellar ataxia type 3. We present evidence that soluble levels of CBP are reduced in cells expressing expanded polyglutamine despite increased levels of CBP mRNA. Finally, we demonstrate that over-expression of CBP rescues cells from polyglutamine-mediated toxicity in neuronal cell culture. These data support a CBP-sequestration model of polyglutamine expansion disease.
Similar articles
-
[Triplet repeat disease, with particular emphasis of spinal and bulbar muscular atrophy (SBMA)].Rinsho Shinkeigaku. 2000 Dec;40(12):1193-5. Rinsho Shinkeigaku. 2000. PMID: 11464455 Japanese.
-
Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.Neurobiol Dis. 2013 Oct;58:49-56. doi: 10.1016/j.nbd.2013.04.019. Epub 2013 May 6. Neurobiol Dis. 2013. PMID: 23659897
-
Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.J Neurochem. 2004 May;89(4):908-18. doi: 10.1111/j.1471-4159.2004.02369.x. J Neurochem. 2004. PMID: 15140190
-
Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Prog Neurobiol. 2011. PMID: 21740957 Review.
-
Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.NeuroRx. 2005 Jul;2(3):480-3. doi: 10.1602/neurorx.2.3.480. NeuroRx. 2005. PMID: 16389311 Free PMC article. Review.
Cited by
-
Complex disease interventions from a network model for type 2 diabetes.PLoS One. 2013 Jun 11;8(6):e65854. doi: 10.1371/journal.pone.0065854. Print 2013. PLoS One. 2013. PMID: 23776558 Free PMC article.
-
Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease.J Clin Invest. 2015 Feb;125(2):831-45. doi: 10.1172/JCI73214. Epub 2015 Jan 20. J Clin Invest. 2015. PMID: 25607844 Free PMC article.
-
Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept.Expert Rev Proteomics. 2010 Aug;7(4):543-64. doi: 10.1586/epr.10.36. Expert Rev Proteomics. 2010. PMID: 20653509 Free PMC article. Review.
-
Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis.Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9310-5. doi: 10.1073/pnas.152101299. Epub 2002 Jun 25. Proc Natl Acad Sci U S A. 2002. PMID: 12084819 Free PMC article.
-
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Protects Striatal Cells and Improves Motor Function in Huntington's Disease Models: Role of PAC1 Receptor.Front Pharmacol. 2022 Jan 28;12:797541. doi: 10.3389/fphar.2021.797541. eCollection 2021. Front Pharmacol. 2022. PMID: 35153755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
